Yes, it is very frustrating. If you read my previous posts about this you'll get the story. Basically, GU was able to secure funding from an AZ foundation while they were having difficulty funding a new PD trial. They still say that they intend to conduct a PD study, however, I don't know that they have the funds yet. Regarding the MJFF et al trials, that was never supposed to happen until later in 2017. It is way to early to be looking for trial sites as they are still designing the trial. There is no information yet on inclusion/exclusion criteria. If GU finds the money, that trial will likely commence earlier than MJFF.

There is also a third trial that you may want to follow. A small biotech company, Inhibikase Therapeutics, has received FDA approval to begin a double-blinded, placebo-controlled trials for Nilotinib and Dasatinib (Sprycel - Bristol-Myers). The trials will try to evaluate the ability of both drugs (vs placebo) to slow or reverse progression in Stage 2 and 3 PD patients. It will be held at one test site over a 6 month period.

The reason Inhibikase is conducting the studies is really more of a proof of concept for two new drugs that they are researching. They are developing two Abelson tyrosine inhibitors that are as much as 60 times more potent than the ones currently on the market (Nilotinib, Dasatinib, Gleevec, etc.).